News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
193,203 Results
Type
Article (18505)
Company Profile (130)
Press Release (174555)
Multimedia
Podcasts (64)
Webinars (13)
Section
Business (58688)
Career Advice (957)
Deals (9507)
Drug Delivery (45)
Drug Development (23718)
Employer Resources (73)
FDA (2467)
Job Trends (4319)
News (93131)
Policy (5859)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (489)
Accelerated approval (15)
Adcomms (16)
Allergies (41)
Alliances (16315)
ALS (75)
Alzheimer's disease (592)
Antibody-drug conjugate (ADC) (186)
Approvals (2457)
Artificial intelligence (219)
Autoimmune disease (84)
Automation (14)
Bankruptcy (83)
Best Places to Work (2891)
BIOSECURE Act (20)
Biosimilars (63)
Biotechnology (117)
Bladder cancer (73)
Brain cancer (28)
Breast cancer (233)
Cancer (1985)
Cardiovascular disease (139)
Career advice (788)
Career pathing (24)
CAR-T (180)
CDC (5)
Cell therapy (467)
Cervical cancer (12)
Clinical research (20418)
Collaboration (912)
Company closure (3)
Compensation (280)
Complete response letters (32)
COVID-19 (779)
CRISPR (46)
C-suite (500)
Cystic fibrosis (62)
Data (2412)
Denatured (13)
Depression (47)
Diabetes (133)
Diagnostics (1158)
Digital health (6)
Diversity (3)
Diversity, equity & inclusion (21)
Drug discovery (143)
Drug pricing (49)
Drug shortages (2)
Duchenne muscular dystrophy (110)
Earnings (17108)
Editorial (28)
Employer branding (8)
Employer resources (73)
Events (33490)
Executive appointments (538)
FDA (3372)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (3)
Frontotemporal dementia (17)
Funding (754)
Gene editing (109)
Generative AI (24)
Gene therapy (369)
GLP-1 (382)
Government (719)
Grass and pollen (1)
Guidances (88)
Healthcare (2405)
HIV (12)
Huntington's disease (33)
IgA nephropathy (53)
Immunology and inflammation (171)
Immuno-oncology (37)
Indications (28)
Infectious disease (887)
Inflammatory bowel disease (104)
Inflation Reduction Act (3)
Influenza (46)
Intellectual property (102)
Interviews (142)
IPO (4177)
IRA (14)
Job creations (1481)
Job search strategy (707)
JPM (43)
Kidney cancer (7)
Labor market (58)
Layoffs (246)
Leadership (26)
Legal (1213)
Liver cancer (24)
Longevity (6)
Lung cancer (223)
Lymphoma (181)
Machine learning (25)
Management (24)
Manufacturing (394)
MASH (54)
Medical device (698)
Medtech (700)
Mergers & acquisitions (5766)
Metabolic disorders (466)
Multiple sclerosis (66)
NASH (8)
Neurodegenerative disease (171)
Neuropsychiatric disorders (40)
Neuroscience (1131)
Neurotech (1)
NextGen: Class of 2026 (1458)
Non-profit (463)
Now hiring (39)
Obesity (254)
Opinion (199)
Ovarian cancer (77)
Pain (61)
Pancreatic cancer (95)
Parkinson's disease (129)
Partnered (16)
Patents (182)
Patient recruitment (183)
Peanut (18)
People (23145)
Pharmaceutical (16)
Phase I (7882)
Phase II (9734)
Phase III (5480)
Pipeline (1893)
Policy (128)
Postmarket research (307)
Preclinical (3242)
Press Release (61)
Prostate cancer (70)
Psychedelics (28)
Radiopharmaceuticals (95)
Rare diseases (402)
Real estate (2466)
Recruiting (40)
Regulatory (5290)
Reports (23)
Research institute (537)
Resumes & cover letters (154)
Rett syndrome (11)
RNA editing (17)
RSV (25)
Schizophrenia (37)
Series A (160)
Series B (108)
Service/supplier (5)
Sickle cell disease (40)
Special edition (16)
Spinal muscular atrophy (53)
Sponsored (16)
Startups (1818)
State (1)
Stomach cancer (7)
Supply chain (32)
Tariffs (37)
The Weekly (51)
Vaccines (344)
Venture capital (81)
Weight loss (156)
Women's health (21)
Worklife (8)
Date
Today (31)
Last 7 days (189)
Last 30 days (958)
Last 365 days (11821)
2026 (970)
2025 (11899)
2024 (12645)
2023 (13201)
2022 (16037)
2021 (16924)
2020 (13174)
2019 (9492)
2018 (7536)
2017 (8975)
2016 (8112)
2015 (9408)
2014 (9724)
2013 (9447)
2012 (6079)
2011 (6451)
2010 (5840)
Location
Africa (334)
Alabama (51)
Alaska (3)
Arizona (72)
Arkansas (2)
Asia (14205)
Australia (2791)
California (4229)
Canada (1188)
China (476)
Colorado (92)
Connecticut (161)
Delaware (100)
Europe (31779)
Florida (510)
Georgia (67)
Hawaii (2)
Idaho (14)
Illinois (211)
India (28)
Indiana (217)
Iowa (7)
Japan (175)
Kansas (24)
Kentucky (6)
Louisiana (6)
Maine (2)
Maryland (548)
Massachusetts (3336)
Michigan (112)
Minnesota (194)
Mississippi (1)
Missouri (29)
Montana (10)
Nebraska (5)
Nevada (32)
New Hampshire (9)
New Jersey (959)
New Mexico (11)
New York (992)
North Carolina (599)
North Dakota (6)
Northern California (2019)
Ohio (97)
Oklahoma (10)
Oregon (11)
Pennsylvania (797)
Puerto Rico (8)
Rhode Island (17)
South America (405)
South Carolina (7)
Southern California (1689)
Tennessee (28)
Texas (574)
United States (14056)
Utah (62)
Virginia (39)
Washington D.C. (24)
Washington State (532)
West Virginia (1)
Wisconsin (32)
193,203 Results for "moleculin biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
January 14, 2026
·
6 min read
Press Releases
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
August 15, 2025
·
3 min read
Press Releases
Moleculin Announces New Annamycin Collaboration in Brain Tumors
December 8, 2025
·
6 min read
Press Releases
Moleculin to Participate in the Virtual Investor Closing Bell Series
November 27, 2025
·
2 min read
Press Releases
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
December 11, 2025
·
5 min read
Press Releases
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
August 7, 2025
·
7 min read
Press Releases
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
January 13, 2026
·
10 min read
Insights
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
January 29, 2026
·
3 min read
·
Jennifer Smith-Parker
Press Releases
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
October 30, 2025
·
5 min read
Press Releases
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
December 18, 2025
·
7 min read
1 of 19,321
Next
